Basal Septal Hypertrophy vs. Ventricular Septal Hypertrophy: Key Distinctions
No, basal septal hypertrophy (BSH) is not the same as ventricular septal hypertrophy—BSH is a specific, localized form of hypertrophy confined to the basal (upper) portion of the interventricular septum, whereas ventricular septal hypertrophy refers to thickening that can involve any or all segments of the septum.
Understanding the Terminology
Basal septal hypertrophy is a focal, isolated thickening limited to the basal (uppermost) portion of the interventricular septum. This represents a distinct anatomical pattern where hypertrophy affects only the upper 1-2 segments of the septum, typically with a basal-to-mid septal thickness ratio ≥1.4 1.
Ventricular septal hypertrophy is a broader term describing thickening anywhere along the entire interventricular septum—from base to apex. This can be diffuse (involving multiple segments) or focal, but is not restricted to the basal region.
Clinical Context and Significance
Basal Septal Hypertrophy
BSH is commonly associated with:
- Systemic hypertension as an early remodeling marker 1, 2
- Elderly patients with prevalence reaching 7.8% over age 70 3
- Age-related changes often considered a benign variant 4
The hypertrophy in BSH typically measures 15-18mm at the base with a characteristic ratio where the hypertrophied area is ≥1.7 times thicker than adjacent septum, but the length of hypertrophied portion is <0.39 of total septal length 5. Importantly, BSH patients generally lack family history of hypertrophic cardiomyopathy (HCM) and rarely show HCM-associated ECG changes 3.
Differentiating from Hypertrophic Cardiomyopathy
According to current guidelines, HCM involves LV wall thickness ≥15mm anywhere in the left ventricle, most commonly affecting the basal anterior septum in continuity with the anterior free wall 6, 7. However, this represents diffuse or extensive hypertrophy, not the isolated focal pattern of BSH.
The critical distinction: While HCM can involve the basal septum, it typically extends beyond this region and is associated with sarcomere gene variants, family history, characteristic ECG changes, and different pathophysiology 6, 7. BSH, conversely, is localized, age-related, and primarily linked to hypertensive heart disease without the genetic substrate of HCM 8.
Diagnostic Pitfalls to Avoid
Don't diagnose HCM based solely on BSH: The presence of isolated basal septal thickening without other HCM features (fiber disarray on histology, family history, characteristic ECG changes, or genetic variants) should not be labeled as HCM 5.
Assess the extent of hypertrophy: Use the basal-to-mid septal ratio and measure the length of hypertrophied segment relative to total septal length to confirm true BSH 1, 9.
Consider left ventricular outflow tract obstruction (LVOTO): Only 3.3% of BSH patients develop resting LVOTO, and this occurs through mitral valve co-aptation abnormalities and LV hypercontractility rather than the degree of septal hypertrophy itself 3.
Use cardiac MRI when uncertain: In patients with type 2 BSH (≥15mm), cardiac MRI helps differentiate from HCM through fibrosis patterns and ventricular morphology 8.
Functional Implications
BSH serves as an early imaging biomarker of hypertensive heart disease 2, associated with:
- Decreased regional LV systolic deformation
- Impaired LV relaxation
- Left atrial functional impairment
- Higher proportion of indeterminate diastolic function 1
These functional changes occur even in well-controlled hypertensive patients, suggesting BSH marks the adaptive phase of remodeling before progression to heart failure 2.